The Pharmacological effects of novokinin; a designed peptide agonist of the angiotensin AT2 receptor

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3009-3012

  Yoshikawa, Masaaki ^a   Ohinata, Kousaku ^a   Yamada, Yuko ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin; AT2receptor; Compound 21; Food intake; Novokinin; Opioid; Prostaglandin; Vasorelaxation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR AGONIST; ANGIOTENSIN II; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; CAY 10441; MORPHINE; NOVOKININ; OVOKININ; PEPTIDE DERIVATIVE; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FOOD INTAKE; KNOCKOUT MOUSE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION;

ANALGESICS, OPIOID; ANIMALS; ANOREXIA; ANTIHYPERTENSIVE AGENTS; HUMANS; MICE; OLIGOPEPTIDES; RECEPTOR, ANGIOTENSIN, TYPE 2; VASODILATOR AGENTS;

EID: 84878666926     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170006     Document Type: Article

References (41)

1. Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-50.
2. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-7. Erratum in: Nature 1996; 380: 366.
3. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 1997; 100: 264-9.
4. 2receptor ligands CGP42112B and PD123319 in the sodium-depleted rat. Eur J Pharmacol 1993; 249: 85-93
5. 2receptor affinity. Bioorg Med Chem 2003; 11: 2947-54.
6. 2receptor agonist. J Med Chem 2004; 47: 5995-6008.
7. 2receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 2009; 27: 44-2451.
8. 2receptors by the nonpeptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159: 709-16.
9. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosa-trienoic acid and inhibition of nuclear factor ttB. Hypertension 2010; 55: 924-31.
10. Jing F, Mogi M, Sakata A, et al. Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab 2012; 32: 248-55.
11. Gao J, Zhang H, Le KD, Chao J, Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens 2011; 24: 724-30.
12. Verdonk K, Durik M, Abd-Alla N, et al. Compound 21 Induces Vasorelaxation via an Endothelium-and Angiotensin II Type 2 Receptor-Independent Mechanism. Hypertension 2012; 60: 722-9.
13. Henschen A, Lottspeich F, Brantl V, Teschemacher H. Novel opioid peptides derived from casein (ee-casomorphins). II. Structure of active components from bovine casein peptone. Hoppe Seylers Z Physiol Chem 1979; 360: 1217-24.
14. Brantl V, Gramsch C, Lottspeich F, Mertz R, Jaeger KH, Herz A. Novel opioid peptides derived from hemoglobin: hemorphins. Eur J Pharmacol 1986; 125: 309-10.
15. Fukudome S, Yoshikawa M. Opioid peptides derived from wheat gluten: their isolation and characterization. FEBS Lett 1992; 296: 107-11.
16. Fukudome S, Yoshikawa M. Gluten exorphin C. A novel opioid peptide derived from wheat gluten. FEBS Lett 1993; 316: 17-9.
17. Yang S, Yunden J, Sonoda S, et al. Rubiscolin, a delta selective opioid peptide derived from plant Rubisco. FEBS Lett 2001; 509: 213-7.
18. 1agonist peptide derived from ovalbumin. Peptides 1995; 16: 785-90.
19. Takahashi M, Moriguchi S, Ikeno M, et al. Studies on the ileumcontracting mechanisms and identification as a complement C3a receptor agonist of oryzatensin, a bioactive peptide derived from rice albumin. Peptides 1996; 17: 5-12.
20. Takahashi M, Moriguchi S, Suganuma H, et al. Identification of casoxin C, an ileum-contracting peptide derived from bovine cc-casein, as an agonist for C3a receptors. Peptides 1997; 18: 329-36.
21. Yamauchi R, Usui H, Yunden J, Takenaka Y, Tani F, Yoshikawa M. Characterization of MM-lactotensin, a bioactive peptide derived from bovine ff-lactoglobulin, as a neurotensin agonist. Biosci Biotechnol Biochem 2003; 67: 940-3.
22. Maruyama S, Nakagomi K, Tomizuka N, Suzuki H. Angiotensin Iconverting enzyme inhibitor derived from an enzymatic hydrolysate of casein. II. Isolation and bradykinin-potentiating activity on the uterus and ileum of rats. Agric Biol Chem 1985; 49: 1405-9.
23. Fujita H, Yoshikawa M. LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology 1999; 44: 123-7.
24. Fujita H, Yokoyama K, Yoshikawa M, Classification and antihypertensive activity of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J Food Sci 2000; 65: 564-9.
25. Matoba N, Usui H, Fujita H, Yoshikawa M. A novel antihypertensive peptide derived from ovalbumin induces nitric oxidemediated vasorelaxation in an isolated SHR mesenteric artery. FEBS Lett 1999; 452: 181-94.
26. Fujita H, Sasaki R, Yoshikawa M. Potentiation of the antihypertensive activity of orally administered ovokinin, a vasorelaxing peptide derived from ovalbumin, by emulsification in egg phosphatidylcholine. Biosci Biotechnol Biochem 1995; 59: 2344-5.
27. Yamada Y, Matoba N, Usui H, Onishi K, Yoshikawa M. Design of a highly potent anti-hypertensive peptide based on ovokinin(2-7). Biosci Biotechnol Biochem 2002; 66: 1213-7.
28. 2receptor and prostaglandin IP receptor. Peptides 2008; 29: 412-8.
29. Matoba N, Yamada Y, Usui H, Nakagiri R, Yoshikawa M. Designing potent derivatives of ovokinin(2-7), an anti-hypertensive peptide derived from ovalbumin. Biosci Biotechnol Biochem 2001; 65: 736-9.
30. Matoba N, Doyama N, Yamada Y, Maruyama N, Utsumi S, Yoshikawa M. Design and production of genetically modified soybean protein with anti-hypertensive activity by incorporating potent analogue of ovokinin(2-7). FEBS Lett 2001; 497: 50-5.
31. Onishi K, Matoba N, Yamada Y, et al. Optimal designing of betaconglycinin to genetically incorporate RPLKPW, a potent antihypertensive peptide. Peptides 2004; 25: 37-43.
32. Yamada Y, Nishizawa K, Yokoo M, et al. Anti-hypertensive activity of genetically modified soybean seeds accumulating novokinin. Peptides 2008; 29: 331-7.
33. Yang L, Tada Y, Yamamoto MP, Zhao H, Yoshikawa M, Takaiwa F. A transgenic rice seed accumulating an anti-hypertensive peptide reduces the blood pressure of spontaneously hypertensive rats. FEBS Lett 2006; 580: 3315-20.
34. Wakasa Y, Zhao H, Hirose S, et al. Antihypertensive activity of transgenic rice seed containing an 18-repeat novokinin peptide localized in the nucleolus of endosperm cells. Plant Biotechnol J 2011; 9: 729-35.
35. 2-and IP-receptor-dependent mechanism in the mesenteric artery from SHRs. Biosci Biotechnol Biochem 2008; 72: 257-9.
36. 2. in "Peptide Science 2009" Ed. By Okamoto K, pp.285-8, The Japanese Peptide Society (2010)
37. 2angiotensin II receptor gene expression in rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res 1996; 37: 192-200.
38. 2-dependent mechanism in mice. Peptides 2009; 30: 1105-8.
39. Kaneko S, Tamura S, Takagi H. Purification and identification of endogenous anti-opioid substances from bovine brain. Biochem Biophys Res Commun. 1985; 126: 587-93.
40. 3receptor in mice. Peptides 2009; 30: 735-9.
41. Wang JQ, Fibuchi EE, Sakurada S, Han JS. Anti-opioid peptides. In "Handbook of Biologically Active Peptides" ed. By Kastin JA, pp.1345-50, Academic Press (2006).